Analyst Flags Kura Oncology, Inc. (KURA) for 2026 Milestones and Pipeline Expansion [Yahoo! Finance]
Kura Oncology, Inc. (KURA)
Last kura oncology, inc. earnings: 2/25 04:03 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.kuraoncology.com/investor-relations
Company Research
Source: Yahoo! Finance
TheFly reported on January 13 that Leerink Partners lowered the price target on KURA to $20 from $25 and maintained an Outperform rating. This revision reflects updates to the model incorporating preliminary Q4 financial results, which include Komzifti's net product revenue, collaboration revenue, and 2026 guidance ahead of the company's Q4 earnings report. In addition, Kura Oncology, Inc. (NASDAQ:KURA) disclosed on January 11 that KOMZIFTI (ziftomenib) generated $2.1 million in net product sales during the first five weeks of commercial availability, which ended on December 31, 2025. The first oral menin inhibitor approved for use once daily in patients with refractory or relapsed NPM1-mutated acute myeloid leukemia (AML) is called KOMZIFTI. The business recognized advancements in all of its TSHA-102 development programs and outlined anticipated 2026 milestones. These accomplishments included expanding ziftomenib into combination regimens and non-AML indications, increasing the
Show less
Read more
Impact Snapshot
Event Time:
KURA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KURA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KURA alerts
High impacting Kura Oncology, Inc. news events
Weekly update
A roundup of the hottest topics
KURA
News
- Kura Oncology (KURA) had its "buy" rating reaffirmed by UBS Group AG.MarketBeat
- Kura Oncology, Inc. (KURA) Presents at Barclays 28th Annual Global Healthcare Conference Transcript [Seeking Alpha]Seeking Alpha
- How The Kura Oncology (KURA) Story Is Shifting With Komzifti And New Street Targets [Yahoo! Finance]Yahoo! Finance
- Kura Oncology (KURA) had its price target lowered by Wedbush from $38.00 to $36.00. They now have an "outperform" rating on the stock.MarketBeat
- Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
KURA
Earnings
- 3/5/26 - Miss
KURA
Sec Filings
- 3/20/26 - Form 4
- 3/5/26 - Form 10-K
- 3/5/26 - Form 8-K
- KURA's page on the SEC website